Next Article in Journal
Anti-Inflammatory Effects of 5α,8α-Epidioxycholest-6-en-3β-ol, a Steroidal Endoperoxide Isolated from Aplysia depilans, Based on Bioguided Fractionation and NMR Analysis
Previous Article in Journal
Nutrient Deprivation-Associated Changes in Green Microalga Coelastrum sp. TISTR 9501RE Enhanced Potent Antioxidant Carotenoids
Open AccessFeature PaperReview

Marine-Derived Anticancer Agents: Clinical Benefits, Innovative Mechanisms, and New Targets

1
REQUIMTE/LAQV, Laboratório de Farmacognosia, Departamento de Química, Faculdade de Farmácia, Universidade do Porto, R. Jorge Viterbo Ferreira, n° 228, 4050-313 Porto, Portugal
2
Department of Chemistry and Biochemistry, University of California, Santa Barbara, CA 93106, USA
3
Department of Neurosurgery, Hôpital Erasme, Université Libre de Bruxelles, 808 Route de Lennik, 1070 Brussels, Belgium
4
Department of Chemistry and Biochemistry, Texas State University, San Marcos, TX 78666, USA
*
Authors to whom correspondence should be addressed.
Mar. Drugs 2019, 17(6), 329; https://doi.org/10.3390/md17060329
Received: 15 May 2019 / Revised: 29 May 2019 / Accepted: 30 May 2019 / Published: 2 June 2019
The role of the marine environment in the development of anticancer drugs has been widely reviewed, particularly in recent years. However, the innovation in terms of clinical benefits has not been duly emphasized, although there are important breakthroughs associated with the use of marine-derived anticancer agents that have altered the current paradigm in chemotherapy. In addition, the discovery and development of marine drugs has been extremely rewarding with significant scientific gains, such as the discovery of new anticancer mechanisms of action as well as novel molecular targets. Approximately 50 years since the approval of cytarabine, the marine-derived anticancer pharmaceutical pipeline includes four approved drugs and eighteen agents in clinical trials, six of which are in late development. Thus, the dynamic pharmaceutical pipeline consisting of approved and developmental marine-derived anticancer agents offers new hopes and new tools in the treatment of patients afflicted with previously intractable types of cancer. View Full-Text
Keywords: cytarabine; trabectedin; eribulin; brentuximab vedotin; plitidepsin; lurbinectedin; plinabulin; marizomib; plocabulin; antibody–drug conjugates cytarabine; trabectedin; eribulin; brentuximab vedotin; plitidepsin; lurbinectedin; plinabulin; marizomib; plocabulin; antibody–drug conjugates
Show Figures

Figure 1

MDPI and ACS Style

Pereira, R.B.; Evdokimov, N.M.; Lefranc, F.; Valentão, P.; Kornienko, A.; Pereira, D.M.; Andrade, P.B.; Gomes, N.G.M. Marine-Derived Anticancer Agents: Clinical Benefits, Innovative Mechanisms, and New Targets. Mar. Drugs 2019, 17, 329.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop